Effect of angiotensin receptor-neprilysin inhibitor treatment on erectile dysfunction in heart failure with a reduced ejection fraction

N.A.

Article Details

Effect of angiotensin receptor-neprilysin inhibitor treatment on erectile dysfunction in heart failure with a reduced ejection fraction

Authors:

N.A.

Publisher:

Marmara University

Main Topics:

Clinical Sciences

Journal:

Marmara Medical Journal Vol.36 Issue 1, pp.99-104

Document Type:

Article

Publication Date:

1/2023

Document Language:

English

Document ID (Org No.):

2001283553

pISSN:

1019-1941

Keywords:

Abstract:

 Objective: Erectile dysfunction ED is a common condition in patients with heart failure HF, which impairs quality of life. Our study aimed to compare those patients, who received traditional treatment with a diagnosis of HF and those who received angiotensin receptor-neprilysin inhibitor ARNI treatment in addition to the current treatment, in terms of ED at the end of 6 months. Patients and Methods: The study was planned as a single-center, prospective study. The study included 200 patients with heart failure. The patients demographic, clinical, and echocardiographic characteristics were recorded, and an international ED scoring questionnaire was applied. The participants in the study were divided into two groups: those who received ARNI treatment and those who did not. After 6 months, the ED questionnaire was applied to the patients again and the groups were compared. Results: The median age of the patients was 53 years. The median ejection fraction EF value was calculated to be 30 and no significant difference was found between the groups p: 0.122. It was found that N-terminal pro-brain natriuretic peptide NT-pro- BNP levels measured at the end of the 6th month were significantly lower in patients who had received ARNI treatment than in those who had not respectively, 245 pgml, 200 pgml; p: 0.003. In the analysis performed to detect the presence of ED, it was discovered that the ED score change was significantly higher in the group that had received 6 months of ARNI treatment p: 0.031 compared to that in the group that had not p: 0.031. When the ED sub-parameters were compared in terms of the 6-month change rate, it was found that the ARNI group had a significant increase in terms of ED and sexual satisfaction scores, but no significant difference was found in the other parameters p: 0.001, p: 0.029. Conclusion: Erectile dysfunction is more common in patients with heart failure compared to the rest of society and impairs quality of life. In our study, it was determined that ED complaints decreased significantly in HF patients, who had received ARNI treatment for 6 months than in patients who had not.

 Objective: Erectile dysfunction ED is a common condition in patients with heart failure HF, which impairs quality of life. Our study aimed to compare those patients, who received traditional treatment with a diagnosis of HF and those who received angiotensin receptor-neprilysin inhibitor ARNI treatment in addition to the current treatment, in terms of ED at the end of 6 months. Patients and Methods: The study was planned as a single-center, prospective study. The study included 200 patients with heart failure. The patients demographic, clinical, and echocardiographic characteristics were recorded, and an international ED scoring questionnaire was applied. The participants in the study were divided into two groups: those who received ARNI treatment and those who did not. After 6 months, the ED questionnaire was applied to the patients again and the groups were compared. Results: The median age of the patients was 53 years. The median ejection fraction EF value was calculated to be 30 and no significant difference was found between the groups p: 0.122. It was found that N-terminal pro-brain natriuretic peptide NT-pro- BNP levels measured at the end of the 6th month were significantly lower in patients who had received ARNI treatment than in those who had not respectively, 245 pgml, 200 pgml; p: 0.003. In the analysis performed to detect the presence of ED, it was discovered that the ED score change was significantly higher in the group that had received 6 months of ARNI treatment p: 0.031 compared to that in the group that had not p: 0.031. When the ED sub-parameters were compared in terms of the 6-month change rate, it was found that the ARNI group had a significant increase in terms of ED and sexual satisfaction scores, but no significant difference was found in the other parameters p: 0.001, p: 0.029. Conclusion: Erectile dysfunction is more common in patients with heart failure compared to the rest of society and impairs quality of life. In our study, it was determined that ED complaints decreased significantly in HF patients, who had received ARNI treatment for 6 months than in patients who had not.

 Objective: Erectile dysfunction ED is a common condition in patients with heart failure HF, which impairs quality of life. Our study aimed to compare those patients, who received traditional treatment with a diagnosis of HF and those who received angiotensin receptor-neprilysin inhibitor ARNI treatment in addition to the current treatment, in terms of ED at the end of 6 months. Patients and Methods: The study was planned as a single-center, prospective study. The study included 200 patients with heart failure. The patients demographic, clinical, and echocardiographic characteristics were recorded, and an international ED scoring questionnaire was applied. The participants in the study were divided into two groups: those who received ARNI treatment and those who did not. After 6 months, the ED questionnaire was applied to the patients again and the groups were compared. Results: The median age of the patients was 53 years. The median ejection fraction EF value was calculated to be 30 and no significant difference was found between the groups p: 0.122. It was found that N-terminal pro-brain natriuretic peptide NT-pro- BNP levels measured at the end of the 6th month were significantly lower in patients who had received ARNI treatment than in those who had not respectively, 245 pgml, 200 pgml; p: 0.003. In the analysis performed to detect the presence of ED, it was discovered that the ED score change was significantly higher in the group that had received 6 months of ARNI treatment p: 0.031 compared to that in the group that had not p: 0.031. When the ED sub-parameters were compared in terms of the 6-month change rate, it was found that the ARNI group had a significant increase in terms of ED and sexual satisfaction scores, but no significant difference was found in the other parameters p: 0.001, p: 0.029. Conclusion: Erectile dysfunction is more common in patients with heart failure compared to the rest of society and impairs quality of life. In our study, it was determined that ED complaints decreased significantly in HF patients, who had received ARNI treatment for 6 months than in patients who had not.

 Objective: Erectile dysfunction ED is a common condition in patients with heart failure HF, which impairs quality of life. Our study aimed to compare those patients, who received traditional treatment with a diagnosis of HF and those who received angiotensin receptor-neprilysin inhibitor ARNI treatment in addition to the current treatment, in terms of ED at the end of 6 months. Patients and Methods: The study was planned as a single-center, prospective study. The study included 200 patients with heart failure. The patients demographic, clinical, and echocardiographic characteristics were recorded, and an international ED scoring questionnaire was applied. The participants in the study were divided into two groups: those who received ARNI treatment and those who did not. After 6 months, the ED questionnaire was applied to the patients again and the groups were compared. Results: The median age of the patients was 53 years. The median ejection fraction EF value was calculated to be 30 and no significant difference was found between the groups p: 0.122. It was found that N-terminal pro-brain natriuretic peptide NT-pro- BNP levels measured at the end of the 6th month were significantly lower in patients who had received ARNI treatment than in those who had not respectively, 245 pgml, 200 pgml; p: 0.003. In the analysis performed to detect the presence of ED, it was discovered that the ED score change was significantly higher in the group that had received 6 months of ARNI treatment p: 0.031 compared to that in the group that had not p: 0.031. When the ED sub-parameters were compared in terms of the 6-month change rate, it was found that the ARNI group had a significant increase in terms of ED and sexual satisfaction scores, but no significant difference was found in the other parameters p: 0.001, p: 0.029. Conclusion: Erectile dysfunction is more common in patients with heart failure compared to the rest of society and impairs quality of life. In our study, it was determined that ED complaints decreased significantly in HF patients, who had received ARNI treatment for 6 months than in patients who had not.

Article Details

Effect of angiotensin receptor-neprilysin inhibitor treatment on erectile dysfunction in heart failure with a reduced ejection fraction

Authors:

N.A.

Publisher:

Marmara University

Main Topics:

Clinical Sciences

Journal:

Marmara Medical Journal Vol.36 Issue 1, pp.99-104

Document Type:

Article

Publication Date:

1/2023

Document Language:

English

Document ID (Org No.):

2001283553

pISSN:

1019-1941

Erectile dysfunction

Heart failure

Angiotensin receptor-neprilysin inhibitor

Erectile dysfunction

Heart failure

Angiotensin receptor-neprilysin inhibitor

Issues

Article Details

Effect of angiotensin receptor-neprilysin inhibitor treatment on erectile dysfunction in heart failure with a reduced ejection fraction

Authors: N.A.

Publisher: Marmara University

Main Topics: Clinical Sciences

Journal: Marmara Medical Journal Vol.36 Issue 1, pp.99-104

Document Type: Article

Publication Date: 1/2023

Document Language: English

Document ID (Org No.): 2001283553

pISSN: 1019-1941

Erectile dysfunction

Heart failure

Angiotensin receptor-neprilysin inhibitor

Erectile dysfunction

Heart failure

Angiotensin receptor-neprilysin inhibitor

Issues

Authors:

N.A.

Publisher:

Marmara University

Main Topics:

Clinical Sciences

Journal:

Marmara Medical Journal Vol.36 Issue 1, pp.99-104

Document Type:

Article

Publication Date:

1/2023

Document Language:

English

Document ID (Org No.):

2001283553

pISSN:

1019-1941